公开(公告)号：US20200339652A1

公开(公告)日：2020-10-29

申请号：US16813248

申请日：2020-03-09

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Dominik MAURER ,  Sebastian BUNK ,  Leonie ALTEN

IPC: C07K14/725 ,  A61K35/12 ,  A61K35/17 ,  A61K35/66 ,  C07K14/435 ,  C12N15/09 ,  C12N15/10

Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200207849A1

公开(公告)日：2020-07-02

申请号：US16736337

申请日：2020-01-07

Applicant: Immatics Biotechnologies GmbH

Inventor： Felix UNVERDORBEN ,  Sebastian BUNK ,  Martin HOFMANN ,  Dominik MAURER ,  Meike HUTT ,  Claudia WAGNER ,  Leonie ALTEN

IPC: C07K16/28 ,  C07K14/725 ,  C07K16/18 ,  C07K14/78 ,  A61P35/00 ,  C07K14/775 ,  C12N5/0783 ,  C12N15/62

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20200088726A1

公开(公告)日：2020-03-19

申请号：US16569691

申请日：2019-09-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andreas MORITZ ,  Dominik MAURER ,  Sebastian BUNK ,  Claudia WAGNER

IPC: G01N33/569 ,  C07K14/74 ,  A61K39/395 ,  A61K38/17

Abstract: The present invention relates to a method for high throughput screening for a TCR-binding peptide ligand/MHC molecule complex, comprising a stabilized peptide-MHC molecule and respective uses of said method. The present invention further relates to polypeptides comprising or consisting of stabilized MHC molecules or peptide binding fragments thereof, pharmaceutical compositions comprising said polypeptides, vaccines comprising said pharmaceutical composition and uses of said vaccine for the manufacturing of a medicament and/or in the prevention of cancer The present invention further relates to nucleic acids encoding said polypeptides and vectors comprising said nucleic acids.

公开(公告)号：US20190016802A1

公开(公告)日：2019-01-17

申请号：US16035412

申请日：2018-07-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Martin HOFMANN ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER

IPC: C07K16/28 ,  C07K16/10

Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.